A novel tetrameric gp3501-470 as a potential Epstein-Barr virus vaccine

Abstract Infectious mononucleosis and B-cell transformation in response to infection with Epstein–Barr virus (EBV) is dependent upon binding of the EBV envelope glycoprotein gp350 to CD21 on B-cells. Gp350-specific antibody comprises most of the EBV neutralizing activity in the serum of infected patients, making this protein a promising target antigen for a prophylactic EBV vaccine. We describe a novel, tetrameric gp350-based vaccine that exhibits markedly enhanced immunogenicity relative to its monomeric counterpart. Plasmid DNA was constructed for synthesis, within transfected CHO cells, of a tetrameric, truncated (a.a. 1–470) gp350 protein (gp350 1–470 ). Tetrameric gp350 1–470 induced ∼20-fold higher serum titers of gp350 1–470 -specific IgG and >19-fold enhancements in neutralizing titers at the highest dose, and was >25-fold more immunogenic on a per-weight basis than monomeric gp350 1–470 . Further, epidermal immunization with plasmid DNA encoding gp350 1–470 tetramer induced 8-fold higher serum titers of gp350 1–470 -specific IgG relative to monomer. Tetrameric gp350 1–470 binding to human CD21 was >24-fold more efficient on a per-weight basis than monomer, but neither tetramer nor monomer mediated polyclonal human B-cell activation. Finally, the introduction of strong, universal tetanus toxoid (TT)-specific CD4+ T-cell epitopes into the tetrameric gp350 1–470 had no effect on the gp350 1–470 -specific IgG response in naive mice, and resulted in suppressed gp350 1–470 -specific IgG responses in TT-primed mice. Collectively, these data suggest that tetrameric gp350 1–470 is a potentially promising candidate for testing as a prophylactic EBV vaccine, and that protein multimerization, using the approach described herein, is likely to be clinically relevant for enhancing the immunogenicity of other proteins of vaccine interest.